Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyka LabsBOM:500259 -3.44%51 Return-on-Tangible-Equity is -35.52% as of Mar. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 51/100 and a GF Value™ of ₹127.60 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Lyka Labs ranks better than 69.31% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lyka Labs's annualized net income for the quarter that ended in Mar. 2026 was ₹-304 Mil. Lyka Labs's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹857 Mil. Therefore, Lyka Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -35.52%.
The historical rank and industry rank for Lyka Labs's Return-on-Tangible-Equity or its related term are showing as below:
BOM:500259'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -219.73 Med: -8.65 Max: 10.64
Current: -11.02
During the past 13 years, Lyka Labs's highest Return-on-Tangible-Equity was 10.64%. The lowest was -219.73%. And the median was -8.65%.
BOM:500259's Return-on-Tangible-Equity is ranked better than 69.31% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs BOM:500259: -11.02
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Lyka Labs Return-on-Tangible-Equity Related Terms
Lyka Labs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Lyka Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -35.52% mean?
Lyka Labs (BOM:500259) has a Return-on-Tangible-Equity of -35.52% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #368 out of 1199 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Lyka Labs' Return-on-Tangible-Equity too high?
Lyka Labs' current Return-on-Tangible-Equity is -35.52%. Based on the distribution chart, Lyka Labs ranks #368 out of 1199 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #368 out of 1199 companies for Return-on-Tangible-Equity. This puts Lyka Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lyka Labs and its competitors. Lyka Labs's current Return-on-Tangible-Equity is -35.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.60, compared to a current price of ₹59.85 — trading 53.1% below its estimated fair value. The current Return-on-Tangible-Equity is -35.52%. Lyka Labs' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Return-on-Tangible-Equity is -35.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹59.85 is trading 53.1% below its estimated GF Value™ of ₹127.60.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Return-on-Tangible-Equity: -35.52%
GF Value™: ₹127.60 vs. price of ₹59.85 (53.1% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score
Get the complete analysis for BOM:500259
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
